drugset / Trial / NCT07508982
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a phase Ib/II study that aims to investigate the safety, tolerability and explore the efficacy of BCL- XL inhibition in participants with high-risk AML.
Timeline
- Start
- 2026-05-22
- Primary completion
- 2029-12-12
- Completion
- 2031-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Intravenous |
| Subject | Pelcitoclax | Small molecule | — | Intravenous |